Mainstay Medical announces reimbursement approval for ReActiv8 in Australia
Dublin, Ireland: 8 June 2020 – Mainstay Medical Holdings plc today announced that ReActiv8, its implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, has been approved for inclusion in the Prostheses List of reimbursed products in Australia, effective as of 1 July 2020. The Prostheses List identifies implantable devices eligible for reimbursement from all private health insurance funds in Australia. This approval follows the December 2019 regulatory approval from the Australian Therapeutic Goods Administration (TGA) for ReActiv8, which confirmed the inclusion of ReActiv8 in the Australian Register of Therapeutic Goods (ARTG), enabling commercialization throughout Australia.
More information on Mainstay’s website.